RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year
BREAKING: Jury In The Stardust Inquests Has Found The Victims Of The Fire Were Unlawfully Killed
Gardaí Carry Out 12 Searches As Part Of An International Operation Targeting Online Fraud
Watch: Chaos in Dubai - Baltinglass Teen's Airport Ordeal Reveals Extent Of Flooding After Record Rainfall
Ikea Boosts Delivery Efficiency For Kildare Customers With New Rathcoole Distribution Centre, Creating 120 Jobs
Woman's Body Found Trapped Under A Car In Wexford
Kildare Restaurant Owner Sounds Alarm As Over 200 Restaurants And Cafes Have Shut This Year
Naas Murder Case: Accused Man, Padraig Delaney, Claims Self-Defence
Dodgy Box Saga In Kildare: King Kong Media Operator Free On Bail As Sentencing Looms
